Matsubara, N. Et Al. 2021. Olaparib efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC) carrying circulating tumor (ct) DNA alterations in BRCA1, BRCA2 or ATM: Results from the PROfound study.. JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.6 .

Matsubara, N., De Bono, J. S., Olmos, D., Procopio, G., Kawakami, S., ÜRÜN, Y., ... van Alphen, R. J.(2021). Olaparib efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC) carrying circulating tumor (ct) DNA alterations in BRCA1, BRCA2 or ATM: Results from the PROfound study.. JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.6.

Matsubara, Nobuaki Et Al. "Olaparib efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC) carrying circulating tumor (ct) DNA alterations in BRCA1, BRCA2 or ATM: Results from the PROfound study.," JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.6, 2021

Matsubara, Nobuaki Et Al. "Olaparib efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC) carrying circulating tumor (ct) DNA alterations in BRCA1, BRCA2 or ATM: Results from the PROfound study.." JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.6, 2021

Matsubara, N. Et Al. (2021) . "Olaparib efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC) carrying circulating tumor (ct) DNA alterations in BRCA1, BRCA2 or ATM: Results from the PROfound study.." JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.6.

@article{article, author={Nobuaki Matsubara Et Al. }, title={Olaparib efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC) carrying circulating tumor (ct) DNA alterations in BRCA1, BRCA2 or ATM: Results from the PROfound study.}, journal={JOURNAL OF CLINICAL ONCOLOGY}, year=2021}